Aim: A limiting factor in advancement of bone marrow based cell therapies is the lack of characterization of cell products delivered to patients. Methods: Using an automated hematology analyzer that can be implemented in clinical setting, the composition of bone marrow aspirates (n = 17 patients) and bone marrow concentrates (n = 12 patients) were assessed. ICC estimates were calculated for measuring reliability. Results: Bone marrow aspirates assessment resulted in excellent reliability for determining white blood cells (ICC - 0.96; 95% CI: 0.92-0.99), red blood cells (ICC - 0.9; 95% CI: 0.77-0.96), platelets (ICC - 0.93; 95% CI: 0.85-0.97) composition. Bone marrow concentrate assessment resulted in excellent reliability for determining white blood cells (ICC - 0.97; 95% CI: 0.93-0.99), platelets (ICC - 0.95; 95% CI: 0.89-0.99) and moderate reliability for red blood cells (ICC - 0.66; 95% CI: 0.36-0.87) composition. Conclusion: Modern automated hematology analyzers could assist to better characterize the cell therapy products to provide reliable and consistent outcomes.
Aim: A limiting factor in advancement of bone marrow based cell therapies is the lack of characterization of cell products delivered to patients. Methods: Using an automated hematology analyzer that can be implemented in clinical setting, the composition of bone marrow aspirates (n = 17 patients) and bone marrow concentrates (n = 12 patients) were assessed. ICC estimates were calculated for measuring reliability. Results: Bone marrow aspirates assessment resulted in excellent reliability for determining white blood cells (ICC - 0.96; 95% CI: 0.92-0.99), red blood cells (ICC - 0.9; 95% CI: 0.77-0.96), platelets (ICC - 0.93; 95% CI: 0.85-0.97) composition. Bone marrow concentrate assessment resulted in excellent reliability for determining white blood cells (ICC - 0.97; 95% CI: 0.93-0.99), platelets (ICC - 0.95; 95% CI: 0.89-0.99) and moderate reliability for red blood cells (ICC - 0.66; 95% CI: 0.36-0.87) composition. Conclusion: Modern automated hematology analyzers could assist to better characterize the cell therapy products to provide reliable and consistent outcomes.
Entities:
Keywords:
Sysmex; automated hematology analyzer; bone marrow aspirate; bone marrow concentrate; cell-based therapy; reliability
Authors: Wendy W Pang; Elizabeth A Price; Debashis Sahoo; Isabel Beerman; William J Maloney; Derrick J Rossi; Stanley L Schrier; Irving L Weissman Journal: Proc Natl Acad Sci U S A Date: 2011-11-28 Impact factor: 11.205
Authors: D F Stroncek; P V Holland; G Bartch; T Bixby; R G Simmons; J H Antin; K C Anderson; R C Ash; B J Bolwell; J A Hansen Journal: Blood Date: 1993-04-01 Impact factor: 22.113
Authors: Jorge Chahla; Nicolas S Piuzzi; Justin J Mitchell; Chase S Dean; Cecilia Pascual-Garrido; Robert F LaPrade; George F Muschler Journal: J Bone Joint Surg Am Date: 2016-09-21 Impact factor: 5.284
Authors: Christopher M Heylman; Tonya N Caralla; Cynthia A Boehm; Thomas E Patterson; George F Muschler Journal: J Regen Med Tissue Eng Date: 2013-09-26
Authors: Okan W Bastian; Michiel Croes; Jacqueline Alblas; Leo Koenderman; Luke P H Leenen; Taco J Blokhuis Journal: Front Immunol Date: 2018-05-01 Impact factor: 7.561
Authors: Christopher J Centeno; Dustin R Berger; Brandon T Money; Ehren Dodson; Christopher W Urbanek; Neven J Steinmetz Journal: Int Orthop Date: 2022-08-06 Impact factor: 3.479